GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-02-22
- Last Posted Date
- 2013-10-28
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT01797419
- Locations
- 🇦🇺
Geelong Hospital, Geelong, Victoria, Australia
🇦🇺Monash Medical Center, Clayton, Australia
🇦🇺Queensland Children's Medical Research Unit, Herston, Australia
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
- Conditions
- Chronic Lymphocytic LeukemiaIndolent Non-Hodgkin's LymphomaMantle Cell LymphomaDiffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2013-02-21
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 66
- Registration Number
- NCT01796470
- Locations
- 🇺🇸
University of Rochester, James P. Wilmot Cancer Center, Rochester, New York, United States
🇺🇸Northwest Medical Specialties, Tacoma, Washington, United States
🇺🇸Signal Point Clinical Research Center, LLC, Middletown, Ohio, United States
A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects
- Conditions
- Cystic FibrosisChronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2013-02-15
- Last Posted Date
- 2014-03-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 7
- Registration Number
- NCT01793649
- Locations
- 🇺🇸
Investigational Site, Chapel Hill, North Carolina, United States
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
- Conditions
- Human Immunodeficiency VirusChronic Hepatitis C
- Interventions
- First Posted Date
- 2013-02-05
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 275
- Registration Number
- NCT01783678
Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
- Conditions
- HIVHIV Infections
- Interventions
- First Posted Date
- 2013-01-31
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 872
- Registration Number
- NCT01780506
- Locations
- 🇺🇸
Kaiser Permanente Los Angeles, Los Angeles, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Mercer University School of Medicine, Macon, Georgia, United States
A Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GS-4774 (GI-13020) at Various Dose Levels and Regimens in Healthy Adults
- Conditions
- Healthy Volunteers
- Interventions
- Biological: GS-4774
- First Posted Date
- 2013-01-30
- Last Posted Date
- 2014-01-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT01779505
- Locations
- 🇺🇸
Celerion, Phoenix, Arizona, United States
Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C
- Conditions
- Post-transplant Hepatitis C
- First Posted Date
- 2013-01-30
- Last Posted Date
- 2014-01-16
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT01779518
Observational Study on Prevalence of Host and Viral Genotypes in Chronic Hepatitis B and Hepatitis C Patients in India
- Conditions
- Hepatitis BHepatitis C
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2015-07-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 1000
- Registration Number
- NCT01772121
- Locations
- 🇮🇳
Civil Hospital, Dawrpui, Aizawl, Mizoram, India
🇮🇳Dharamsi Hospital,Chandni Chowk, South Shivajinagar, Sangli, Mahashtra, India
🇮🇳Manipal Hospitals,98, HAL Airport Road, Bangalore, Karnataka, India
Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- First Posted Date
- 2013-01-16
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 544
- Registration Number
- NCT01769196
- Locations
- 🇺🇸
Sarasota Memorial Hospital, Sarasota, Florida, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection
- First Posted Date
- 2013-01-15
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 441
- Registration Number
- NCT01768286